Le Lézard
Classified in: Health, Science and technology
Subjects: CCA, FVT

Akero Therapeutics to Present at the Jefferies 2019 London Healthcare Conference


SAN FRANCISCO, Nov. 13, 2019 /PRNewswire/ -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage biotechnology company developing transformational treatments for patients with non-alcoholic steatohepatitis (NASH) and other serious metabolic disorders, today announced that members of the management team will provide a business overview and update at the Jefferies 2019 London Healthcare Conference at 8:00 a.m. GMT on Wednesday, November 20, 2019.

A live webcast of the presentation will be available through the investor relations section of the Company's website at www.akerotx.com. Following the live webcast, an archived replay will be available on the Company's website.

About Akero Therapeutics
Akero Therapeutics is a clinical-stage biotechnology company focused on the development and commercialization of transformative treatments for patients with NASH and other serious metabolic diseases with high unmet medical need. The Company's lead program AKR-001 is being evaluated in a Phase 2a clinical trial for the treatment of NASH. AKR-001 is an engineered human Fc-FGF21 fusion protein designed to harness the inherent benefits of an endogenous hormone called FGF21, with the potential to reduce liver fat, mitigate inflammation, and reverse fibrosis in NASH patients. Akero Therapeutics is headquartered in San Francisco, CA. For more information, please visit www.akerotx.com.

 

(PRNewsfoto/Akero Therapeutics, Inc.)

 

SOURCE Akero Therapeutics, Inc.


These press releases may also interest you

at 02:30
AfterPay Insights' end of June research - now covering more than 7.600 interviews with Dutch online shoppers - indicates that Dutch consumers will reduce their overall purchases in July (i.e. both online and offline purchases). At the same time,...

at 02:27
Hikvision, an IoT solution provider with video as its core competency, today announced a brand-new addition to its DeepinView camera line: the Dedicated Subseries. This unprecedented new addition loads a batch of AI-powered deep learning...

at 02:00
DocPath ZippyDocs, a document software solution for logistics operators, that was launched in 2018, and recently further improved, helps logistic companies to optimize the document delivery and yields significant savings. A set of independent...

at 02:00
Fimatix has today announced the appointment of Tim Howarth as Managing Director for Financial Services, where he will lead the company's work supporting the financial services sector. He will drive the growth of the business through further...

at 01:35
Propeller Health today announced a collaboration with Novartis to co-package the Propeller digital health platform with Enerzair® Breezhaler® (QVM149; indacaterol acetate, glycopyrronium bromide and mometasone furoate [IND/GLY/MF]), a recently...

at 01:30
OpenSynergy, today announced its yearlong collaboration with Google and Qualcomm on a reference platform with a virtualized Android Automotive OS instance running on top of OpenSynergy's COQOS Hypervisor SDK and Qualcomm's Snapdragon SA8155...



News published on 13 november 2019 at 16:01 and distributed by: